CRSP:NASDAQ
Crispr Therapeutics AG
51,63Â $
arrow_downward
−1,36%(−0,71) 1 p
51,42Â $
arrow_downward
−0,41% (−0,21)bedtimePärast tööaega
Suletud: 1. mai, 16:00:01 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse CRSP põhistatistika genereerimine…
Ava
51,59Â $
Kõrge
52,56Â $
Madal
50,59Â $
Turu kapit.
4,98Â mld
Keskm. maht
2,13Â mln
Maht
1,04Â mln
52 näd kõrgeim
78,48Â $
52 näd madalaim
33,03Â $
Aktsiatulu
−6,47 $
Beeta
1,32
Käibivad aktsiad
96,43Â mln
Töötajate arv
393
Uudised
Erinevatest veebiallikatest
Simply Wall Street
·
16 tunni eest
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress
MarketBeat
·
2 päeva eest
UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP
Stock Titan
·
3 päeva eest
ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP)
Profiil
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Teave üksuse Crispr Therapeutics AG kohta
TegevjuhtSamarth Kulkarni
Töötajad393
Asutatud2013
PeakontoridZug, Zugi kanton, Å veits
Sektor-
Veebisaitcrisprtx.com
AI genereeritud sisu võib sisaldada vigu. Lisateave